[go: up one dir, main page]

CA2626859A1 - Traitement anti-tnf-alpha destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur - Google Patents

Traitement anti-tnf-alpha destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur Download PDF

Info

Publication number
CA2626859A1
CA2626859A1 CA002626859A CA2626859A CA2626859A1 CA 2626859 A1 CA2626859 A1 CA 2626859A1 CA 002626859 A CA002626859 A CA 002626859A CA 2626859 A CA2626859 A CA 2626859A CA 2626859 A1 CA2626859 A1 CA 2626859A1
Authority
CA
Canada
Prior art keywords
antibody
enterocolitis
tnf
patients
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002626859A
Other languages
English (en)
Inventor
Steven Fischkoff
Israel Lowy
Michael Yellin
James Chung-Yin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2626859A1 publication Critical patent/CA2626859A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002626859A 2005-11-08 2006-11-08 Traitement anti-tnf-alpha destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur Abandoned CA2626859A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73496305P 2005-11-08 2005-11-08
US60/734,963 2005-11-08
PCT/US2006/043691 WO2007056540A2 (fr) 2005-11-08 2006-11-08 Traitement anti-tnf$g(a) destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur

Publications (1)

Publication Number Publication Date
CA2626859A1 true CA2626859A1 (fr) 2007-05-18

Family

ID=38023997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002626859A Abandoned CA2626859A1 (fr) 2005-11-08 2006-11-08 Traitement anti-tnf-alpha destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur

Country Status (8)

Country Link
US (1) US7611702B2 (fr)
EP (1) EP1948214A4 (fr)
JP (1) JP2009514977A (fr)
CN (1) CN101300024A (fr)
AU (1) AU2006311475A1 (fr)
CA (1) CA2626859A1 (fr)
IL (1) IL190183A0 (fr)
WO (1) WO2007056540A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2630157C (fr) 2005-12-07 2018-01-09 Medarex, Inc. Regimes d'escalade de dose d'anticorps ctla-4
WO2007120626A2 (fr) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
RU2015148676A (ru) * 2009-10-26 2019-01-15 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
US9382329B2 (en) * 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2015153864A2 (fr) * 2014-04-02 2015-10-08 Hopkins Patricia T Méthodes de traitement d'états inflammatoires
WO2016064969A1 (fr) 2014-10-21 2016-04-28 Sciclone Pharmaceuticals, Inc. Traitement du cancer au moyen de stimulateurs immunitaires
EP3227683B1 (fr) 2014-12-05 2019-04-24 Nestec S.A. Dosages hmsa (homogeneous mobility shift assay) indirects pour la détection de substances biologiques dans des échantillons prélevés chez des patients
US10918737B2 (en) 2016-01-28 2021-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
JP2020509037A (ja) 2017-02-28 2020-03-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ワクチンに対する免疫応答を増強するための、ａｄｃｃが増強された抗ｃｔｌａ−４抗体の使用
WO2020114616A1 (fr) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci
AU2020480890A1 (en) 2020-12-09 2023-07-27 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFα BISPECIFIC ANTIBODY, AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (fr) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Peptides immunotherapeutiques se liant a ctla-4
PL210435B1 (pl) 1998-12-23 2012-01-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne wiążące się z CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease

Also Published As

Publication number Publication date
EP1948214A4 (fr) 2009-12-30
US7611702B2 (en) 2009-11-03
WO2007056540A2 (fr) 2007-05-18
JP2009514977A (ja) 2009-04-09
CN101300024A (zh) 2008-11-05
US20070248595A1 (en) 2007-10-25
EP1948214A2 (fr) 2008-07-30
AU2006311475A1 (en) 2007-05-18
WO2007056540A3 (fr) 2007-12-21
IL190183A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
US7611702B2 (en) TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
US20070243184A1 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
CN102209556B (zh) 改良的抗cd19抗体
CN110072890A (zh) 可活化的抗ctla-4抗体及其用途
CN104402999A (zh) Trail受体结合剂和其用途
US11685787B2 (en) Treatment of cancer with anti-GITR agonist antibodies
ZA200510125B (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
KR20150094621A (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
TW202005985A (zh) 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
Tai et al. Antibody‐based therapies in multiple myeloma
JP7193628B2 (ja) 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用
KR20230131464A (ko) 항-cd19 병용 요법
JP2020521777A (ja) 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム
US20240052050A1 (en) Multispecific antibodies for the treatment of cancer
CA3140210A1 (fr) Fluoresceine sodique en tant qu'agent d'inversion pour des cellules car-t anti-fluoresceine et des ethers de fluoresceine-phospholipide ou des ethers de phospholipides-phospholipides
US12144859B2 (en) B cell depleting agent for the treatment of atherosclerosis
US20080152655A1 (en) Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
US20240336688A1 (en) Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
WO2023098785A1 (fr) Anticorps anti-4-1bb et son utilisation
JP7578613B2 (ja) ガンを処置するための、ポリクローナル抗体と抗ｐｄ１又は抗ｐｄｌ１抗体との組み合わせ
US20230416388A1 (en) Treatment of cancer with anti-gitr agonist antibodies
US20250127915A1 (en) Anti-cldn-18.2 antibody-drug conjugate and use thereof
CN118922208A (zh) 用于消耗患病造血干细胞的组合物和方法
WO2017070567A1 (fr) Anticorps de klebsiella pneumoniae et méthodes de traitement des infections à klebsiella pneumoniae
NZ719768A (en) Means and methods for treating dlbcl

Legal Events

Date Code Title Description
FZDE Discontinued